BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 11507059)

  • 21. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
    Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
    Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
    Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
    Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
    Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
    Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
    Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.
    Nagasawa J; Mizokami A; Koshida K; Yoshida S; Naito K; Namiki M
    Int J Urol; 2006 May; 13(5):587-92. PubMed ID: 16771730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.
    Xia Q; Sung J; Chowdhury W; Chen CL; Höti N; Shabbeer S; Carducci M; Rodriguez R
    Cancer Res; 2006 Jul; 66(14):7237-44. PubMed ID: 16849572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
    Jackson JK; Gleave ME; Yago V; Beraldi E; Hunter WL; Burt HM
    Cancer Res; 2000 Aug; 60(15):4146-51. PubMed ID: 10945622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
    Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K
    Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
    Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
    Wallner L; Dai J; Escara-Wilke J; Zhang J; Yao Z; Lu Y; Trikha M; Nemeth JA; Zaki MH; Keller ET
    Cancer Res; 2006 Mar; 66(6):3087-95. PubMed ID: 16540658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
    Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
    Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling.
    Wells A; Souto JC; Solava J; Kassis J; Bailey KJ; Turner T
    Clin Cancer Res; 2002 Apr; 8(4):1251-7. PubMed ID: 11948140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1.
    Choi ES; Shim JH; Jung JY; Kim HJ; Choi KH; Shin JA; Nam JS; Cho NP; Cho SD
    Cancer Sci; 2011 Apr; 102(4):742-8. PubMed ID: 21241418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist.
    Fishman P; Bar-Yehuda S; Ardon E; Rath-Wolfson L; Barrer F; Ochaion A; Madi L
    Anticancer Res; 2003; 23(3A):2077-83. PubMed ID: 12894581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-17 receptor-like gene is a novel antiapoptotic gene highly expressed in androgen-independent prostate cancer.
    You Z; Shi XB; DuRaine G; Haudenschild D; Tepper CG; Lo SH; Gandour-Edwards R; de Vere White RW; Reddi AH
    Cancer Res; 2006 Jan; 66(1):175-83. PubMed ID: 16397230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
    Kim SJ; Uehara H; Yazici S; Langley RR; He J; Tsan R; Fan D; Killion JJ; Fidler IJ
    Cancer Res; 2004 Jun; 64(12):4201-8. PubMed ID: 15205332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
    Yazici S; Kim SJ; Busby JE; He J; Thaker P; Yokoi K; Fan D; Fidler IJ
    Prostate; 2005 Nov; 65(3):203-15. PubMed ID: 15948138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis.
    Singh RP; Sharma G; Dhanalakshmi S; Agarwal C; Agarwal R
    Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):933-9. PubMed ID: 14504208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.